EMEA Backs Conditional Marketing Of GSK’s Tykerb, Withdrawal Of Novartis’ Prexige In EU
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK to supply additional data for breast cancer drug; panel okays generics for Roche’s CellCept.